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Background: Although active Mycobacterium tuberculosis (MTB) or Mycobacterium Kansasii (MK) infection could be
present in patients with metastatic colorectal cancer (m-CRC), no study is available on the clinical courses and
chemotherapy outcomes of these patients. The present study therefore aimed to retrospectively examine whether
m-CRC patients with and without active MTB or MK infection could receive cancer chemotherapy similarly.
Methods: This study enrolled 30 m-CRC patients who received first-line chemotherapy between January 31, 2006
and January 31, 2013 at our institution, The clinical courses and tumor response of those with and without active
MTB or MK infection were examined and compared.
Results: Of 30 m-CRC patients, 6 had active MTB infection, 1 with active MK and the other 23 had neither MTB nor
MK. No significant demographic differences were observed between patients with MTB or MK and those without.
Chemotherapy response rates of all patients, those with MTB or MK, and those without were 40.0%, 28.6% and
43.5%, respectively. Among patients with MTB or MK, 1 treated with bevacizumab experienced grade-3 hemoptysis
while others did not report any severe toxicity. Median survival time of all studied patients, those with MTB or MK,
and those without was 26.3, 36.7 and 22.6 months, respectively. No significant difference in overall survival was
observed between patients with MTB or MK and those without. Multivariate analysis revealed that performance
status and liver metastasis were significant prognostic factors of overall survival (P = 0.004 and 0.030, respectively),
whereas other factors, including MTB or MK infection, were not. In our study, all 7 patients with MTB or MK did
not experience infection relapse during or after cancer chemotherapy.
Conclusions: Our results indicate that m-CRC patients with MTB or MK should be able to safely and effectively
continue cancer chemotherapy to subsequently achieve comparable survival duration to those without the infection if
they receive proper MTB or MK treatment.
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Colorectal cancer (CRC) is the third most commonly diag-
nosed cancer in males and the second in females in 2008
[1]. The disease incidence rates are rapidly increasing in
parts of Eastern Asia including Korea and the urban area
of China, Eastern Europe, and Brazil [2,3]. Particularly, the
rate in Japan has exceeded the peak value observed in
countries where incidence rates are declining or stabilizing
such as the United States, Canada, and Australia [2,3].
Mycobacterium tuberculosis (MTB) is the second leading
cause of death from an infectious disease worldwide [4]. In
2012, most MTB cases occurred in Asia (58%) and Africa
(27%). The disease incidence and mortality rates in Japan
are obviously higher than those in other developed coun-
tries in North America and Western Europe [4].
Our institution is established as a medical center for re-
spiratory diseases such as lung cancer, chronic obstructive
pulmonary diseases, bronchial asthma, interstitial lung dis-
eases, and various pulmonary infections including MTB
and non-tuberculosis mycobacterium (NTM). Therefore,
patients with abnormal findings by chest radiography or
computed tomography (CT), or suspicious MTB infection
are often referred to us. As a result, our medical oncolo-
gists, in collaboration with other specialists, have adminis-
tered cancer chemotherapy in metastatic colorectal cancer
(m-CRC) patients with multiple lung metastases, respira-
tory diseases including bronchial asthma and chronic ob-
structive pulmonary diseases, and MTB or NTM infection.
Although active MTB or NTM infection could be present
in patients with m-CRC, no study is available on the clinical
courses and chemotherapy outcomes of these patients. In
this present study, we first reported that if proper tu-
berculosis management was provided, m-CRC patients
with active MTB could concurrently receive both cancer
chemotherapy and MTB treatment safely and effectively.
Methods
Study approval
The present retrospective study was approved by the Insti-
tutional Review Board of the Osaka Prefectural Medical
Center for Respiratory and Allergic Diseases on October
23, 2013 (approval number: 654).
Patient selection
Patients with m-CRC who received first-line chemotherapy
between January 31, 2006 and January 31, 2013 at our insti-
tution were included. Those receiving adjuvant chemother-
apy or eligible for surgical treatments of lung metastasis or
liver metastasis were excluded from this study.
Clinical review
Clinical history of eligible patients was retrospectively
reviewed. Baseline demographics information including sex,
age, Eastern Cooperative Oncology Group performancestatus (PS), histology, and disease stage at the beginning
of first-line chemotherapy was obtained for each patient.
Furthermore, chemotherapy data including regimen, num-
ber of cycles and dose, and the start and stop date of each
regimen were collected from clinical records or pharmacy
database. At the time of first-line chemotherapy, the follow-
ing data were available for all patients: a complete history
and physical examination, surgical reports, colonoscopy
findings, imaging investigations (chest radiography, abdo-
men radiography and CT, brain CT or magnetic resonance
imaging, abdominal CT, and bone scintigraphy or positron
emission tomography), pathologic reports, and blood test
results.Serum carcinoembryonic antigen (CEA)
Serum CEA levels (ng/mL) were assessed for inoperable
or relapsed CRC at the beginning of and after first-line
chemotherapy per our institutional routine protocol. The
upper limit of normal range was 5 ng/mL.Genetic testing for K-ras mutation
Tissue samples from enrolled patients were sent at the
appropriate time to SRL, Inc. (Tokyo, Japan) for K-ras
mutation analysis. The cost of such procedure is covered by
the Japanese medical insurance system for m-CRC patients.Chemotherapeutic regimens
At our institution, intensive regimens for first-line chemo-
therapy included fluorouracil/leucovorin plus oxaliplatin
(FOLFOX) [5], fluorouracil/leucovorin plus irinotecan
(FOLFIRI) [6], or capecitabine plus oxaliplatin (XELOX)
administered with or without bevacizumab (Bmab) [7-9]
or anti-epidermal growth factor receptor antibody such as
cetuximab (Cmab) [10,11] and panitumumab (Pmab) [12].
Patients could also receive second-line chemotherapy with
intensive regimens different from the first-line. Addition-
ally, those with poor PS or sever complications received
different regimens from the intensive ones for either first-
or second-line chemotherapy. Treatment was discontinued
in cases of disease progression, unacceptable side effects,
or at a patient’s request.Best response to first-line chemotherapy
Response Evaluation Criteria in Solid Tumors (RECIST)
[13] were used to evaluate treatment response during
weekly discussion at our institution. Patients’ best response
to first-line chemotherapy was collected from records
of these meetings and physicians’ summaries. Based on
RECIST criteria, a tumor response to cytotoxic agents
was categorized as partial response (PR), stable disease
(SD), or progressive disease (PD). A tumor response that
was not assessable was noted as not evaluable (NE).
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Sputum smears and cultures were routinely tested for acid-
fast bacilli with 3-day consecutive sputa if the patient was
producing sputum. For patients incapable of producing
a sputum sample, common alternative sample sources
for mycobacterium diagnosis included those from gastric
washing or bronchoscopy. In most patients without a
microbiological evaluation, mycobacterium diagnosis was
assessed by chest CT imaging.
The preferred method for mycobacterium infection
determination was fluorescence microscopy study and
Ziehl-Neelsen staining of sputum smear samples [14], of
which results were reported within 24 hours of testing. If a
sputum smear was positive, polymerase chain reaction
(PCR) or loop-mediated isothermal amplification of DNA
[15] could be performed to distinguish MTB from other
mycobacteria, and the result of such procedure was re-
ported within 2 days. If sputum smear was negative or
specimens other than sputum were obtained from a pa-
tient, a definitive diagnosis of mycobacterial infection
was made by culturing mycobacterial organisms from
such a specimen. Sputum specimens from smear-positive
MTB patients were also cultured for drug sensitivity.
Liquid media with Mycobacteria Growth Indicator Tube
[16] and solid media with Ogawa-Kudoh method [17]
were both used for mycobacterial culture. Quantitative
drug susceptibility testing for MTB was performed by
MTB-I® (Kyokuto Pharmaceutical Industrial Co., LTD,
Tokyo) modified Minimum Inhibitory Concentration
method [18].Treatment of MTB or MK infection
Treatment strategy for patients with MTB or NTM in-
cluding MK infection was discussed weekly at our meet-
ings on infectious diseases. m-CRC patients with MTB
infection started cancer chemotherapy after being treated
with appropriate MTB drugs according to the American
Thoracic Society (ATS) and the Infectious Diseases
Society of America (IDSA) guidelines [19] for approxi-
mately one and a half months. It was required that MTB
bacillus was not multi-drug resistant in a sensitivity test
for cancer chemotherapy to be initiated. Among patients
with NTM, only those with MK were treated similar to
MTB patients according to a modified regimen based on
ATS and IDSA guidelines [20]. Thus, MTB patients re-
ceived a standard treatment including two months of a
drug combination containing isoniazid (H), rifampicin (R),
ethambutol (E), and pyrazinamide (P) (2HREZ), followed
by four months of daily H and R (4HR). Those with MK
infection received 12HR to 18HR. However, as MTB pa-
tients with severe complication often expected a longer
treatment than those without, those treated with cancer
chemotherapy received long-term treatment for MTB.Follow-up MTB or MK culture
After MTB or MK treatment started, sputum culture was
performed bi-weekly for the first three months. When re-
sults of two consecutive sputum cultures were negative, the
procedure was conducted monthly until the completion of
MTB or MK treatment.
Definition of MTB or MK treatment success
MTB or MK treatment success was comprised of a cure
and a treatment completion. A cure was defined as both
the completion of a planned treatment and the negativity
of two consecutive cultures, whereas a treatment comple-
tion was considered as the former alone.
Statistical analysis
Survival time was defined as the time from the initiation
date of fist-line chemotherapy to the date of death or the
last follow-up. Survival data were updated on October 31,
2013. Survival rates were estimated by the Kaplan-Meier
method [21]. Differences among survival curves were
assessed using the log-rank test. Variables with a P-value
of <0.05 on univariate analysis were included in the multi-
variate analysis with Cox’s regression model to identify
independent predictors of survival. All analyses were con-
ducted using the statistical software package R [22].




Thirty patients with inoperable or relapsed m-CRC who
received fist-line chemotherapy at our institution between
January 1, 2006 and 2013 January 31 were included in this
study. Among these, 11 patients were complicated with
respiratory diseases, including 6 with active MTB infection
and 1 with active MK. Table 1 summarizes the character-
istics of all patients (N = 30), those with MTB or MK in-
fection (N = 7), and those without MTB or MK infection
(N = 23). No differences in sex, age, PS, serum CEA levels,
and K-ras status were observed between patients with
MTB or MK infection and those without. Of 30 patients,
15 had recurrence after CRC surgery and 15 were diag-
nosed at stage IV of the disease. Of 15 stage IV patients, 7
underwent palliative surgery for stenosis or obstruction in
the colon or rectum.
Chemotherapy regimens and response to first-line
chemotherapy
Table 2 presents the first-line chemotherapy, which was
categorized into intensive regimens and non-intensive reg-
imens, for all m-CRC patients (N = 30), those with active
MTB or MK infection (N = 7), and those without (N = 23).
Of 30 enrolled patients, 1 achieved CR; 11 had PR; 10 had
SD, and 7 had PD. The response rates (RR) of all patients,
Table 1 Patient demographics
Variable Overall MTB or MK
(+) (–)
Total 30 7 23
Sex (male/female) 20/10 5/2 15/8




Primary site (rectum/colon) 17/13 5/2 12/11
Stage (IV/relapse) 15/15 5/2 10/13




Lung 18 4 14
Liver 13 4 9
Peritoneum 8 1 7
Abdominal lymph node 5 1 4
Bone 5 0 5
Mediastinal lymph node 4 0 4
Others 2 0 2
Serum CEA (ng/mL) level









Others 2 0 2
CEA: carcinoembryonic antigen, MTB: Mycobacterium tuberculosis, MK:
Mycobacterium kansasii, COPD: chronic obstructive pulmonary disease.
Table 2 Chemotherapy regimens, number of cycles and
patients’ response to first-line chemotherapy
Regimens of first-line
chemotherapy
Overall MTB or MK infection
(+) (–)
N = 30 N = 7 N = 23
Intensive regimens 26 6 20
FOLFOX 8 2 6
FOLFOX + Bmab 6 1 5
FOLFIRI 6 1 5
FOLFOX + Pmab/Cmab 2 2 0
FOLFIRI + Pmab/Cmab 2 0 2
FOLFIRI + Bmab 1 0 1
XELOX 1 0 1
Non-intensive regimens 4 1 3
UFT/LV 1 1 0
S-1 2 0 2
Capecitabine 1 0 1
Response rate (%) 40.0 28.6 43.5
CR 1 1 0
PR 11 1 10
SD 10 2 8
PD 7 3 4
NE 1 0 1
CR: complete response, PR: partial response, SD: stable disease,
PD: progression disease, NE: not evaluable, RR: response rate.
FOLFOX: folinic acid, fluorouracil, oxaliplatin, Bmab: bevacizumab,
FOLFIRI: folinic acid, fluorouracil, irinotecan, Pmab: panitumumab,
Cmab: cetuximab, XELOX: capecitabine plus oxaliplatin,
UFT/LV: uracil/tegafur/leucovorin.
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were 40.0%, 28.6% and 43.5%, respectively. Of 2 MTB
or MK responders, 1 was treated with FOLFOX plus
Cmab, while the other received FOLFOX. Among 10 re-
sponders without MTB/MK infection, 5 were treated
with FOLFOX+ Bmab, 2 with FOLFOX, and 1 each with
FOLFIRI alone, FOLFIRI + Bmab, or FOLFIRI + Pmab.
None of the 4 patients who received non-intensive regi-
mens achieved PR or CR.
Second-line chemotherapy and others
Of 7 patients with MTB or MK infection, 4 received
second-line chemotherapy after disease progression,
whereas 2 with poor PS did not due to cancer death
after first-line chemotherapy, and 1 with CR did not owing
to the well-maintained CR. All 4 patients who received
second-line chemotherapy achieved PR or SD, with 2 of
them currently receiving fourth- and fifth-line chemother-
apy, respectively.Seventeen of 21 patients without MTB or MK infection
received second-line chemotherapy, whereas 3 did not
due to cancer death; 2 continued first-line chemotherapy
with SD, and 1 was followed up only after discontinuation
of first-line chemotherapy.Thoracic CT findings in m-CRC patients with MTB or MK
infection
Figure 1 shows thoracic CT findings in patients with MTB
or MK infection. These CT images (A–D) presented a
combination of cavity of the lung with thick or thin wall,
infiltration shadows, and patty follicular spot.Diagnosis for MTB or MK infection in m-CRC patients
Table 3 shows the clinical features of 7 m-CRC patients
with MTB or MK infection at the beginning of first-line
chemotherapy. Of these, 2 were diagnosed by both spu-
tum smear and culture for MTB, 2 by MTB-PCR and
culture, 1 by MTB culture only, 1 by MK culture only, and
1 by CT imaging only.
Figure 1 Thoracic computed tomography findings in patients with MTB or MK infection. A: Cavity formation with thick wall. B: Infiltration
shadow in bilateral lungs and cavity formation in the right upper lobe. C: Infiltration shadow with patty follicular spot in the bilateral lungs.
D: Cavity formation with thick wall in the left upper lobe.
Table 3 Clinical outcomes of CRC patients with MTB or MK infection




Time from the beginning of MTB or MK therapy until the
start of first-line chemotherapy (days)
MTB or MK
treatment success
A CT imaging 6HRE/6HR 16 Completion
B Sputum TB-PCR (+), MTB culture (+) 2HREZ/7HR 104 Cure
C Sputum smear (+), MTB culture (+) 24HE 408 Cure
D Sputum smear (+), MK culture (+) 18HRE 56 Cure
E Sputum smear (-), MTB culture (+) 9HRE 25 Cure
F Sputum smear (-), Sputum TB-PCR (+),
MTB culture (+)
6HRE/6HR 19 Cure
G Sputum smear (+), MTB culture (+) 12RE 53 Cure
Patient First-line chemotherapy Regimen Best
response
Side effects (grade ≥ 3) due to cancer chemotherapy or MTB or MK
treatment
A UFT/LV SD -
B FOLFOX6 + Cmab CR -
C FOLFOX6 PD Liver dysfunction due to MTB treatment
D FOLFOX6 + Pmab PD -
E FOLFOX6 + Bmab SD Hemoptysis due to Bmab
F FOLFOX6 PR -
G FOLFIRI PD -
MTB: Mycobacterium tuberculosis, MK: Mycobacterium kansasii, CT: computed tomography, TB-PCR: tuberculosis polymerase chain reaction.
H: isoniazid, R: rifampicin, E: ethambutol, Z: pyrazinamide.
nHREZ: n months of H, R, E and Z combination.
CR: complete response, PR: partial response, SD: stable disease, PD: progression disease.
FOLFOX: folinic acid, fluorouracil, oxaliplatin, Bmab: bevacizumab, FOLFIRI: folinic acid, fluorouracil, irinotecan, Pmab: panitumumab, Cmab: cetuximab,
XELOX: capecitabine plus oxaliplatin, UFT/LV: uracil/tegafur/leucovorin.
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Six of 7 patients with MTB or MK achieved a cure for their
infection, whereas the other one completed the planned
treatment with an improvement of chest CT imaging.
None of these experienced MTB or MK infection relapses
during or after cancer chemotherapy.
Time to first-line chemotherapy from the beginning of
MTB or MK therapy
The median time to first-line chemotherapy from the be-
ginning of MTB or MK therapy was 53 days (range, 16 to
408 days). Patient C who waited 408 days received S-1 as
adjuvant chemotherapy for gastric cancer for 6 months and
concurrent MTB treatment during that time. After approxi-
mately 1 year, the patient was diagnosed with m-CRC and
subsequently received CRC chemotherapy and additional
MTB treatment for approximately 10 months.
Side effects due to first-line chemotherapy or MTB
treatment
Of 7 m-CRC patients with MTB or MK, patient C expe-
rienced grade-3 liver dysfunction due to rifampicin while
receiving S-1 for post-operative adjuvant chemotherapy
for gastric cancer. After the diagnosis of m-CRC, patient
C received both cancer chemotherapy for CRC and a regi-
men containing HE and ofloxacin. Patient E who was
treated with FOLFOX + Bmab as first-line chemother-
apy experienced grade-3 hemoptysis after 2 cycles. After
discontinuation of Bmab, the patient was treated safely with
FOLFOX until PD.
Overall survival and prognostic factors
As shown in Figure 2, the median survival time (MST)
of all enrolled m-CRC patients was 26.3 months. Figure 3
shows the survival curves of patients with MTB or MK
infection and those without, and the MST was 36.7 and
22.6 months, respectively. No significant survival differ-
ences were observed between both groups (P = 0.536).
As shown in Table 4, PS and liver metastasis were iden-
tified as significant prognostic factors of survival by both
univariate (P = 0.002 and 0.020, respectively) and multi-
variate (P = 0.004 and 0.030, respectively) analyses, whereas
other factors were not significantly correlated with survival.
Discussion
The present study indicate that patients with active MTB
or MK infection could safely receive both cancer chemo-
therapy and effective MTB or MK treatment, and subse-
quently achieved a MST of 36.7 months, which was
comparable to previously published results [23,24]. Our
findings therefore suggest that if effective MTB or MK
treatment is provided, cancer chemotherapy could be ad-
ministered in m-CRC patients with MTB or MK infection
similarly to those without. However, although we achievedan overall RR of 40% for first-line chemotherapy, which
was comparable to those previously reported 40–50%
[23,24], patients with MTB or MK infection had a lower
RR of 28.9%. Possible explanations to such a result could be
that 4 of 7 patients with MTB or MK infection received
intensive regimens without molecular targeted agents or
non-intensive regimen, and the other one who received
FOLFOX+Bmab discontinued the treatment due to grade-
3 hemoptysis after 2 cycles. Since patients with MTB or
MK infection frequently have cavity lesions in the lung or
expectorate hemosputum, they would have high risk for
hemoptysis. Therefore, when grade-3 hemoptysis was
observed, we decided not to provide Bmab-containing
regimens to these patients to avoid hemoptysis death at
first-line chemotherapy. Such a decision might lead to
the low RR in patients with MTB or MK infection. How-
ever, despite a low RR to first-line chemotherapy, these pa-
tients achieved a MST of 36.7 months. Of 7 patients with
MTB or MK infection, 4 received second-line or further
chemotherapy to achieve SD or PR, whereas 1 maintained
CR with first-line chemotherapy only. Except for the early
deaths of 2 patients with poor PS, the remaining 5 experi-
enced long-term survival.
As Falagas et al. [25] described in their review article,
MTB and cancer are very common diseases but there
has been little attention to the pathophysiological and
practical implications of their co-existence. Most clinical
studies selected in their review article [25] were case re-
ports except for several case series and reviews, and all
diagnoses were based on biopsies from the same site of
infection and malignancy or from regional lymph nodes
instead of acid fast bacterium culture. In this study, pri-
mary CRC lesions did not co-exist with MTB in the lungs,
and each lesion was diagnosed separately. Furthermore,
most cases examined in the review article [25] had re-
ceived variable treatments for MTB prior to, concurrent
with, or after cancer therapy. In our study, even if the
patients expectorated sputum positive for MTB, they
concurrently received cancer chemotherapy and MTB
treatment after being diagnosed with both diseases. Since
there is no study similar to ours, we confirmed in this study
that m-CRC patients with MTB or MK should be able to
safely and effectively receive cancer chemotherapy similar
to those without.
Regarding MTB and cancer, previous studies reported
that MTB was linked to the development of pyothorax as-
sociated lymphoma [26,27] and lung cancer [28,29]. How-
ever, there is no study available on the correlation between
CRC development and MTB. Therefore, the co-existence
of MTB and CRC in this study is thought to occur by
chance.
Countries and areas such as Brazil, Eastern Asia, South-
Eastern Asia, and India are those burdened with MTB in-
fection [4]. In addition, a recent study [30] has shown that
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Figure 3 Survival curve of colorectal cancer patients with MTB or MK and those without. The median survival time of patients with MTB or
MK infection and those without was 36.7 and 22.6 months, respectively. Dashed line indicates the survival curve of patients with MTB or MK,
whereas solid line represents that of those without. No significant differences were observed between the two groups (P = 0.536).
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Table 4 Univariate and multivariate analyses of overall survival (N = 30)
Variable N MST P value/HR (95% CI)
(Months) Univariate Multivariate
Sex
Male 20 29.4 0.458
Female 10 22.6 1.44 (0.54–3.81)
Age
<69 14 29.4 0.569
≥69 16 22.6 1.30 (0.53–3.16)
Performance status
0–1 19 36.1 0.002 0.004
2–4 11 11.4 4.06 (1.58–10.43) 4.11 (1.57–10.76)
CEA (ng/ml)
<16.9 14 29.4 0.386
≥16.9 16 22.6 1.51 (0.59–0.82)
K-ras
Wild-type 12 17.4 0.051
Mutated 14 36.7 0.357 (0.12–1.05)
Stage
Relapse after surgery 15 36.7 0.453
IV 15 22.6 1.42 (0.56–3.59)
Respiratory diseases
No 19 22.6 0.875
Yes 11 29.4 0.93 (0.37–2.34)
MTB or MK infection
No 23 22.6 0.536
Yes 7 36.7 0.705 (0.23–2.15)
Primary site
Rectum 16 29.4 0.322
Colon 14 22.6 0.615 (0.23–1.62)
Number of metastatic organs
1 13 36.7 0.0893
≥2 17 16.9 2.2 (0.87–5.58)
Lung metastasis
No 12 16.9 0.483
Yes 18 29.4 0.72 (0.29–1.79)
Liver metastasis
No 17 36.1 0.020 0.030
Yes 13 11.9 3.24 (1.15–9.11) 3.37 (1.13–10.07)
HR: hazard ratio, CI: confidence interval, MST: median survival time.
CEA: carcinoembryonic antigen, MTB: Mycobacterium tuberculosis, MK: Mycobacterium kansasii.
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incidences of CRC. The number of CRC patients with
MTB may increase in these countries. However, no publica-
tion is available on the clinical courses and cancer chemo-
therapy outcomes of CRC patients with MTB infection.To the best of our knowledge, this study was the first
to demonstrate that m-CRC patients with active MTB or
MK infection were able to safely and effectively continue
both cancer chemotherapy and MTB or MK treatment
concurrently, and did not experience relapse of MTB or
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cessful MTB or MK treatment.
The limitations of this study included its retrospective
design and small cohort of patients. Thus, it remains un-
clear whether its results would be generalized for other
solid tumors or at other institutions.
Conclusions
Our results indicate that m-CRC patients with MTB or
MK should be able to safely and effectively continue can-
cer chemotherapy to subsequently achieve comparable
survival duration to those without the infection if they re-
ceive proper MTB or MK treatment. As a result, we plan
to prospectively examine the safety and efficacy of cancer
chemotherapy and concurrent MTB treatment in patients
with CRC or other solid tumors having active MTB
infection.
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